MSCL — Satellos Bioscience Share Price
Last trade - 00:00- CA$54.14m
- CA$14.55m
- 30
- 31
- 98
- 52
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.33 | ||
| Price to Tang. Book | 1.47 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -39.06% | ||
| Return on Equity | -72.15% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Satellos Bioscience Inc. is a Canada-based a drug discovery and development company with a focus on muscle regeneration. The Company is focused on developing medicines to treat degenerative muscle conditions. Its MyoReGenX platform is specifically designed to recreate the specialized muscle stem cell niche in vitro. MyoReGenX platform enables to map pathways which modulate muscle repair and regeneration, identify, and confirm drug targets, and test drug candidates for their ability to restore muscle stem cell repair mechanisms that have been impaired by genetic mutations, disease or injury. Its lead program is an oral, small molecule drug candidate in development as a disease-modifying treatment for Duchenne muscular dystrophy. Its iCo portfolio includes Oral Amp B Delivery System, a patented oral transport technology and Bertilimumab a human monoclonal eotaxin antibody with potential to treat a range of allergic and inflammatory conditions mediated by eotaxin-1.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- August 13th, 2021
- Public Since
- December 1st, 2006
- No. of Employees
- 12
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Toronto Stock Exchange
- Shares in Issue
- 112,791,658
- Address
- 200 Bay Street, Suite 2800, TORONTO, M5J 2J1
- Web
- https://satellos.com/
- Phone
- +1 6476601780
- Auditors
- MNP LLP
Upcoming Events for MSCL
Similar to MSCL
AEterna Zentaris
Toronto Stock Exchange
Antibe Therapeutics(Pre-Merger)
Toronto Stock Exchange
Appili Therapeutics
Toronto Stock Exchange
Aptose Biosciences
Toronto Stock Exchange
Avicanna
Toronto Stock Exchange
FAQ
As of Today at 19:18 UTC, shares in Satellos Bioscience are trading at CA$0.48. This share price information is delayed by 15 minutes.
Shares in Satellos Bioscience last closed at CA$0.48 and the price had moved by -35.14% over the past 365 days. In terms of relative price strength the Satellos Bioscience share price has underperformed the Toronto Stock Exchange 300 Composite Index by -38.84% over the past year.
The overall consensus recommendation for Satellos Bioscience is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Satellos Bioscience does not currently pay a dividend.
Satellos Bioscience does not currently pay a dividend.
Satellos Bioscience does not currently pay a dividend.
To buy shares in Satellos Bioscience you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.48, shares in Satellos Bioscience had a market capitalisation of CA$54.14m.
Here are the trading details for Satellos Bioscience:
- Country of listing: Canada
- Exchange: TOR
- Ticker Symbol: MSCL
Based on an overall assessment of its quality, value and momentum Satellos Bioscience is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Satellos Bioscience is CA$1.20. That is 150% above the last closing price of CA$0.48.
Analysts covering Satellos Bioscience currently have a consensus Earnings Per Share (EPS) forecast of -CA$0.14 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Satellos Bioscience. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +16.5%.
As of the last closing price of CA$0.48, shares in Satellos Bioscience were trading +1.37% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Satellos Bioscience PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.48.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Satellos Bioscience's management team is headed by:
- William Jarosz - CHM
- Andrew Rae - CEO
- W. John Meekison - CFO
- Richard Barker - IND
- Noel Hall - IND